Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 8, 2015, Pages 1293-1300

  Kazankov, Konstantin ^a,b   Tordjman, Joan ^b,c   Møller, Holger Jon ^a   Vilstrup, Hendrik ^a   Poitou, Christine ^b,c   Bedossa, Pierre ^d,e   Bouillot, Jean Luc ^f   Clement, Karine ^b,c   Grønbæk, Henning ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^e BEAUJON HOSPITAL   (France)

^f HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Fibrosis; Inflammation; Macrophages; Non alcoholic steatohepatitis; Obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; CD163 ANTIGEN; CHOLESTEROL; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; MESSENGER RNA; SOLUBLE CD163 ANTIGEN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BARIATRIC SURGERY; BILIRUBIN BLOOD LEVEL; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENDOCRINE FUNCTION TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIVER BIOPSY; LIVER CELL; LIVER HISTOLOGY; LIVER INJURY; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; POLYMERASE CHAIN REACTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; BLOOD; COMPLICATION; INSULIN RESISTANCE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; PATHOLOGY; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SOLUBILITY; TIME FACTOR;

ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BARIATRIC SURGERY; BIOMARKERS; FEMALE; HUMANS; INSULIN RESISTANCE; MACROPHAGE ACTIVATION; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; PERIOPERATIVE PERIOD; RECEPTORS, CELL SURFACE; SEVERITY OF ILLNESS INDEX; SOLUBILITY; TIME FACTORS;

EID: 84937391895     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12943     Document Type: Article

References (34)

1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011; 34: 274-285.
2. Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol. 2013; 10: 627-636.
3. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J. Hepatol. 2009; 51: 212-223.
4. Moestrup SK, Moller HJ. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann. Med. 2004; 36: 347-354.
5. Weaver LK, Hintz-Goldstein KA, Pioli PA etal. Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J. Leukoc. Biol. 2006; 80: 26-35.
6. Moller HJ. Soluble CD163. Scand. J. Clin. Lab. Invest. 2012; 72: 1-13.
7. Waidmann O, Brunner F, Herrmann E, Zeuzem S, Piiper A, Kronenberger B. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. J. Hepatol. 2013; 58: 956-961.
8. Kazankov K, Barrera F, Moller HJ etal. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology 2014; 60: 521-530.
9. Holland-Fischer P, Gronbaek H, Sandahl TD etal. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut 2011; 60: 1389-1393.
10. Gronbaek H, Sandahl TD, Mortensen C, Vilstrup H, Moller HJ, Moller S. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. Aliment. Pharmacol. Ther. 2012; 36: 173-180.
11. Carolan E, Hogan AE, Corrigan M etal. The impact of childhood obesity on inflammation, innate immune cell frequency, and metabolic microRNA expression. J. Clin. Endocrinol. Metab. 2014; 99: E474-478.
12. Parkner T, Sorensen LP, Nielsen AR etal. Soluble CD163: a biomarker linking macrophages and insulin resistance. Diabetologia 2012; 55: 1856-1862.
13. Moller HJ, Frikke-Schmidt R, Moestrup SK, Nordestgaard BG, Tybjaerg-Hansen A. Serum soluble CD163 predicts risk of type 2 diabetes in the general population. Clin. Chem. 2011; 57: 291-297.
14. Lassailly G, Caiazzo R, Pattou F, Mathurin P. Bariatric surgery for curing NASH in the morbidly obese? J. Hepatol. 2013; 58: 1249-1251.
15. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
17. Moller HJ, Hald K, Moestrup SK. Characterization of an enzyme-linked immunosorbent assay for soluble CD163. Scand. J. Clin. Lab. Invest. 2002; 62: 293-299.
18. Kleiner DE, Brunt EM, Van NM etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
19. Bedossa P, Poitou C, Veyrie N etal. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012; 56: 1751-1759.
20. Aron-Wisnewsky J, Tordjman J, Poitou C etal. Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. J. Clin. Endocrinol. Metab. 2009; 94: 4619-4623.
21. Chalasani N, Younossi Z, Lavine JE etal. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-1609.
22. Zanni MV, Burdo TH, Makimura H, Williams KC, Grinspoon SK. Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects. Clin. Endocrinol. (Oxf) 2012; 77: 385-390.
23. Kazankov K, Moller HJ, Lange A etal. The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children. Pediatr. Obes. 2014; doi: 10.1111/ijpo.252. [Epub ahead of print]
24. Fjeldborg K, Christiansen T, Bennetzen M, Moller J, Pedersen SB, Richelsen B. The macrophage-specific serum marker, soluble CD163, is increased in obesity and reduced after dietary-induced weight loss. Obesity (Silver Spring) 2013; 21: 2437-2443.
25. Tomita K, Tamiya G, Ando S etal. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006; 55: 415-424.
26. Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production. J. Biol. Chem. 2012; 287: 40161-40172.
27. Lefkowitch JH, Haythe JH, Regent N. Kupffer cell aggregation and perivenular distribution in steatohepatitis. Mod. Pathol. 2002; 15: 699-704.
28. Caballero T, Gila A, Sanchez-Salgado G etal. Histological and immunohistochemical assessment of liver biopsies in morbidly obese patients. Histol. Histopathol. 2012; 27: 459-466.
29. Fotiadu A, Gagalis A, Akriviadis E etal. Clinicopathological correlations in a series of adult patients with non-alcoholic fatty liver disease. Pathol. Int. 2010; 60: 87-92.
30. Itoh M, Kato H, Suganami T etal. Hepatic crown-like structure: a unique histological feature in non-alcoholic steatohepatitis in mice and humans. PLoS ONE 2013; 8: e82163.
31. Walenbergh SM, Koek GH, Bieghs V, Shiri-Sverdlov R. Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins. J. Hepatol. 2013; 58: 801-810.
32. Leroux A, Ferrere G, Godie V etal. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J. Hepatol. 2012; 57: 141-149.
33. Ruiz AG, Casafont F, Crespo J etal. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes. Surg. 2007; 17: 1374-1380.
34. Fiorentino L, Vivanti A, Cavalera M etal. Increased tumor necrosis factor alpha-converting enzyme activity induces insulin resistance and hepatosteatosis in mice. Hepatology 2010; 51: 103-110.